We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

dinsdag 7 februari 2017

The Lancet: [Articles] Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in p...

[Articles] Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
Our results support the efficacy of cariprazine in the treatment of predominant negative symptoms of schizophrenia.
Read more

[Correspondence] Trump's ban on colleagues from Islamic countries
President Trump has closed the borders of the United States for all citizens from a selected group of Islamic countries.1 This ban will affect a large number of our colleague surgeons and physicians in their work as clinicians and academics. We view this as unjustified and unacceptable discrimination on the basis of religion, citizenship and culture.
Read more

[Articles] Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study
In patients with primary biliary cholangitis with pruritus, 14 days of ileal bile acid transporter inhibition by GSK2330672 was generally well tolerated without serious adverse events, and demonstrated efficacy in reducing pruritus severity. GSK2330672 has the potential to be a significant and novel advance for the treatment of pruritus in primary biliary cholangitis. Diarrhoea, the most common adverse event associated with GSK2330672 treatment, might limit the long-term use of this drug.
Read more

[Comment] Accounting for the future of health in India
On Feb 1, 2017, the Government of India's Finance Minister Arun Jaitley presented the annual Union Budget in Parliament.1 Within it, ambitious "action plans" for improving health or ameliorating disease were referenced. The plans include the elimination of several infectious diseases—visceral leishmaniasis and filariasis in 2017, leprosy by 2018, measles by 2020, and tuberculosis by 2025. Beyond disease control, national laws and regulations are to be amended or implemented to reduce the costs of medicines and medical devices nationwide, while harmonising regulations with international standards in order to attract investment into this sector.
Read more

[Comment] An appealing new agent for treating cholestatic pruritus
Management of cholestatic pruritus is challenged by the uncertainty of its pathogenesis, which is related to various components of bile, but could also be mediated by increased opioidergic neurotransmission and other pathways.1 Ursodeoxycholic acid (UDCA) does not ameliorate cholestatic itch except in intrahepatic cholestasis of pregnancy. Resins such as cholestyramine and colestipol are widely used as first-line treatments although the evidence base for these interventions is small.2 Moreover, patients can have poor tolerance because of taste and abdominal disturbances, and might discontinue therapy.
Read more